Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 6/20 | 0.35 |
| ▸ | PPARG | P37231 | 4/20 | 0.35 |
| ▸ | DHFR | P00374 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7338915 | 0.89 | PPARA (0.34) | PPARAPPARGDHFRPOLBNPSR1 | |
| SCHEMBL9139332 | 0.86 | DHFR (0.36) | PPARAPPARGDHFRPOLBNPSR1 | |
| SCHEMBL1515781 | 0.86 | PIM3 (0.34) | MAPTPPARAPPARGDHFR | |
| SCHEMBL9137815 | 0.81 | DRD2 (0.40) | PPARGPOLBNPSR1HMGCRDRD2 | |
| SCHEMBL7342222 | 0.77 | PPARA (0.34) | PPARAPPARGDHFR | |
| SCHEMBL7332445 | 0.77 | PPARA (0.32) | PPARAPPARGPOLBNPSR1 | |
| SCHEMBL13404080 | 0.77 | NPSR1 (0.39) | MAPTPOLBNPSR1DRD2 | |
| SCHEMBL9131385 | 0.77 | PPARA (0.49) | PPARAPPARGPOLB | |
| SCHEMBL9128937 | 0.76 | THRB (0.37) | MAPTPOLBNPSR1 | |
| SCHEMBL6155473 | 0.73 | CA12 (0.38) | MAPTPPARAPPARGDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046308-A1 | NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME | KOWA COMPANY, LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
| EP-0617001-B1 | Phenoxyphenylacetic acid derivatives | MERCK & CO INC (US) | 2000-01-26 | — | — | EP | disclosed |
| US-5767310-A | Phenoxyphenylacetic acid derivatives | MERCK & CO., INC. (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0774965-A4 | PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO INC (US) | 1997-10-29 | — | — | EP | disclosed |
| US-5668176-A | ENDOTHELIN ANTAGONIST | MERCK & CO. INC. (US) | 1997-09-16 | — | — | US | disclosed |
| EP-0774965-A1 | PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO. INC. (US) | 1997-05-28 | — | — | EP | disclosed |
| US-5565485-A | TREATING CARDIOVASCULAR DISORDERS | MERCK & CO., INC. (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996009818-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EMESIS | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
| WO-1996004905-A1 | PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1996-02-22 | — | — | WO | disclosed |
| US-5449682-A | Angiotensin II antagonists incorporating a substituted benzyl element | MERCK & CO., INC. (US) | 1995-09-12 | — | — | US | disclosed |
| US-5374638-A | Cardiovascular disorders, hypotensive agents | MERCK & CO., INC. (US) | 1994-12-20 | — | — | US | disclosed |
| WO-1994021255-A1 | SIX-MEMBERED RING FUSED IMIDAZOLES SUBSTITUTED WITH PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| WO-1994021590-A1 | PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| EP-0617001-A1 | Phenoxyphenylacetic acid derivatives | MERCK & CO. INC. (US) | 1994-09-28 | — | — | EP | disclosed |
| US-5334598-A | Have endothelin antagonist activity; useful in treating cardiovascular disorders, hypertension, inflammatory diseases and asthma | MERCK & CO., INC. (US) | 1994-08-02 | — | — | US | disclosed |
| US-5246944-A | Hypotensive and anxiolytic agents; antidepressants | MERCK & CO., INC. (US) | 1993-09-21 | — | — | US | disclosed |
| US-5240938-A | Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring | MERCK & CO., INC. (US) | 1993-08-31 | — | — | US | disclosed |
| EP-0527534-A1 | Quinoline and azaquinoline angiotensin II antagonists | MERCK & CO. INC. (US) | 1993-02-17 | — | — | EP | disclosed |
| WO-1991011999-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046308-A1 | NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME | PPARA, PPARG, PPARD | MAPT 4322/4885PPARA 1/4885PPARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.